Brought to you by 
Forest,Paion end stroke collaboration
29 Oct 2020
Executive Summary
Forest Laboratories and Paion GMBH (developing drugs for stroke and other thrombotic diseases) will jointly develop and market, in the US and Canada, Paion's ischemic stroke candidate desmoteplase, a Phase II plasminogen activator (a blood clot-dissolving agent) that was recently granted fast-track status for an expedited FDA review.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forest,Paion end stroke collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice